Stewart AK - Search Results

1

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.

Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Kapoor P, et al. Among authors: stewart ak. Blood. 2009 Jul 16;114(3):518-21. doi: 10.1182/blood-2009-01-202010. Epub 2009 Mar 26. Blood. 2009. PMID: 19324902 Free PMC article.

2

Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma.

Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Stewart AK, et al. Blood. 1999 Jun 15;93(12):4441. Blood. 1999. PMID: 10391696 Free article. No abstract available.

3

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK. Plowright EE, et al. Among authors: stewart ak. Blood. 2000 Feb 1;95(3):992-8. Blood. 2000. PMID: 10648414 Free article.

4

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.

Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Hawley RG, Stewart AK. Li Z, et al. Among authors: stewart ak. Blood. 2001 Apr 15;97(8):2413-9. doi: 10.1182/blood.v97.8.2413. Blood. 2001. PMID: 11290605 Free article.

5

Genetics and cytogenetics of multiple myeloma: a workshop report.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Fonseca R, et al. Among authors: stewart ak. Cancer Res. 2004 Feb 15;64(4):1546-58. doi: 10.1158/0008-5472.can-03-2876. Cancer Res. 2004. PMID: 14989251

6

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

Chang H, Qi C, Yi QL, Reece D, Stewart AK. Chang H, et al. Among authors: stewart ak. Blood. 2005 Jan 1;105(1):358-60. doi: 10.1182/blood-2004-04-1363. Epub 2004 Aug 31. Blood. 2005. PMID: 15339849 Free article.

7

Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.

Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Chang H, et al. Among authors: stewart ak. Blood. 2005 Jul 1;106(1):353-5. doi: 10.1182/blood-2005-01-0033. Epub 2005 Mar 10. Blood. 2005. PMID: 15761022 Free article.

8

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.

Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, Mikhael J, Reece D, Stewart AK. Chang H, et al. Among authors: stewart ak. Bone Marrow Transplant. 2005 Nov;36(9):793-6. doi: 10.1038/sj.bmt.1705131. Bone Marrow Transplant. 2005. PMID: 16113669

9

Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.

Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK. Jaksic W, et al. Among authors: stewart ak. J Clin Oncol. 2005 Oct 1;23(28):7069-73. doi: 10.1200/JCO.2005.17.129. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129840

10

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Stewart AK, Fonseca R. Stewart AK, et al. J Clin Oncol. 2005 Sep 10;23(26):6339-44. doi: 10.1200/JCO.2005.05.023. J Clin Oncol. 2005. PMID: 16155017 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

462 results

Search Page